Advertisement

Tumor stiffness measurement using magnetic resonance elastography can predict recurrence and survival after curative resection of hepatocellular carcinoma

Published:December 06, 2022DOI:https://doi.org/10.1016/j.surg.2022.11.001

      Abstract

      Background

      Tumor stiffness measurement using magnetic resonance elastography can assess tumor mechanical properties and predict hepatocellular carcinoma recurrence. This study aimed to investigate preoperative tumor stiffness on magnetic resonance elastography as a predictor of overall survival and recurrence-free survival in patients with solitary nodular hepatocellular carcinoma who underwent curative resection.

      Methods

      Seventy-eight patients with solitary nodular hepatocellular carcinoma who underwent preoperative magnetic resonance elastography and curative resection were retrospectively analyzed. Potential associations of tumor stiffness and other clinicopathological variables with overall survival and recurrence-free survival were analyzed in both univariate and multivariate Cox proportional hazards analyses. The optimal tumor stiffness cutoff value was determined using the minimal P value approach.

      Results

      In multivariate analysis, tumor stiffness (hazard ratio 1.31; 95% confidence interval, 1.07–1.59; P = .008) and vascular invasion (hazard ratio 2.62; 95% confidence interval, 1.27–5.17; P = .010) were independent predictors of recurrence-free survival. For overall survival, tumor stiffness (hazard ratio, 1.33; 95% confidence interval, 1.02–1.76; P = .037) was the only independent predictor. The optimal tumor stiffness cutoff value was 5.81 kPa for both overall survival and recurrence-free survival. Patients with tumor stiffness ≥5.81 kPa had a significantly greater risk of death (hazard ratio 6.10; 95% confidence interval, 2.11–21.90; P < .001) than those with tumor stiffness <5.81 kPa.

      Conclusion

      Preoperative tumor stiffness as measured by magnetic resonance elastography was a predictor of overall survival and recurrence-free survival in hepatocellular carcinoma patients who underwent curative resection. Higher tumor stiffness was associated with higher risk of recurrence and death.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Reig M.
        • Forner A.
        • Rimola J.
        • et al.
        BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.
        J Hepatol. 2022; 76: 681-693
        • Bruix J.
        • Reig M.
        • Sherman M.
        Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.
        Gastroenterology. 2016; 150: 835-853
        • Pinero F.
        • Dirchwolf M.
        • Pessoa M.G.
        Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment.
        Cells. 2020; 9: 1370
        • Colecchia A.
        • Schiumerini R.
        • Cucchetti A.
        • et al.
        Prognostic factors for hepatocellular carcinoma recurrence.
        World J Gastroenterol. 2014; 20: 5935-5950
        • Hayashi M.
        • Matsui O.
        • Ueda K.
        • et al.
        Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium.
        AJR Am J Roentgenol. 1999; 172: 969-976
        • Choi J.W.
        • Lee J.M.
        • Kim S.J.
        • et al.
        Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR images and their value as an imaging biomarker.
        Radiology. 2013; 267: 776-786
        • Yin M.
        • Talwalkar J.A.
        • Glaser K.J.
        • et al.
        Assessment of hepatic fibrosis with magnetic resonance elastography.
        Clin Gastroenterol Hepatol. 2007; 5: 1207-1213
        • Huwart L.
        • Sempoux C.
        • Vicaut E.
        • et al.
        Magnetic resonance elastography for the noninvasive staging of liver fibrosis.
        Gastroenterology. 2008; 135: 32-40
        • Pepin K.M.
        • Ehman R.L.
        • McGee K.P.
        Magnetic resonance elastography (MRE) in cancer: technique, analysis, and applications.
        Prog Nucl Magn Reson Spectrosc. 2015; (90–91:32–48)
        • Ichikawa S.
        • Motosugi U.
        • Enomoto N.
        • et al.
        Magnetic resonance elastography can predict development of hepatocellular carcinoma with longitudinally acquired two-point data.
        Eur Radiol. 2019; 29: 1013-1021
        • Lee D.H.
        • Lee J.M.
        • Yi N.J.
        • et al.
        Hepatic stiffness measurement by using MR elastography: prognostic values after hepatic resection for hepatocellular carcinoma.
        Eur Radiol. 2017; 27: 1713-1721
        • Venkatesh S.K.
        • Yin M.
        • Glockner J.F.
        • et al.
        MR elastography of liver tumors: preliminary results.
        AJR Am J Roentgenol. 2008; 190: 1534-1540
        • Thompson S.M.
        • Wang J.
        • Chandan V.S.
        • et al.
        MR elastography of hepatocellular carcinoma: correlation of tumor stiffness with histopathology features. Preliminary findings.
        Magn Reson Imaging. 2017; 37: 41-45
        • Wang J.
        • Shan Q.
        • Liu Y.
        • et al.
        3D MR elastography of hepatocellular carcinomas as a potential biomarker for predicting tumor recurrence.
        J Magn Reson Imaging. 2019; 49: 719-730
        • Lu P.
        • Weaver V.M.
        • Werb Z.
        The extracellular matrix: a dynamic niche in cancer progression.
        J Cell Biol. 2012; 196: 395-406
        • Liu Z.
        • Mo H.
        • Liu R.
        • et al.
        Matrix stiffness modulates hepatic stellate cell activation into tumor-promoting myofibroblasts via E2F3-dependent signaling and regulates malignant progression.
        Cell Death Dis. 2021; 12: 1134
        • Park S.J.
        • Yoon J.H.
        • Lee D.H.
        • et al.
        Tumor stiffness measurements on MR elastography for single nodular hepatocellular carcinomas can predict tumor recurrence after hepatic resection.
        J Magn Reson Imaging. 2021; 53: 587-596
        • Venkatesh S.K.
        • Yin M.
        • Ehman R.L.
        Magnetic resonance elastography of liver: technique, analysis, and clinical applications.
        J Magn Reson Imaging. 2013; 37: 544-555
        • Yoshimitsu K.
        • Mitsufuji T.
        • Shinagawa Y.
        • et al.
        MR elastography of the liver at 3.0 T in diagnosing liver fibrosis grades: preliminary clinical experience.
        Eur Radiol. 2016; 26: 656-663
        • Abe H.
        • Midorikawa Y.
        • Higaki T.
        • et al.
        Magnetic resonance elastography-based prediction of hepatocellular carcinoma recurrence after curative resection.
        Surgery. 2021; 170: 167-172
        • Kokudo N.
        • Hasegawa K.
        • Akahane M.
        • et al.
        Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines).
        Hepatol Res. 2015; 45
        • Takayama T.
        • Makuuchi M.
        • Kubota K.
        • et al.
        Randomized comparison of ultrasonic vs clamp transection of the liver.
        Arch Surg. 2001; 136: 922-928
        • Dindo D.
        • Demartines N.
        • Clavien P.-A.
        Classification of surgical complications.
        Ann Surg. 2004; 240: 205-213
        • The Liver Cancer Study Group of Japan
        The General Rules for the Clinical and Pathological Study of Primary Liver Cancer.
        6th ed. Kanehara & Co, Ltd, Tokyo, Japan2015 (revised version)
        • Bedossa P.
        • Poynard T.
        An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.
        Hepatology. 1996; 24: 289-293
        • Yagi R.
        • Midorikawa Y.
        • Moriguchi M.
        • et al.
        Liver resection for recurrent hepatocellular carcinoma to improve survivability: a proposal of indication criteria.
        Surgery. 2018; 163: 1250-1256
        • Kokudo N.
        • Takemura N.
        • Hasegawa K.
        • et al.
        Clinical Practice Guidelines for Hepatocellular Carcinoma 2017 (4th JSH-HCC Guidelines) 2019 update.
        Hepatol Res. 2019; 49: 1109-1113
        • Davidson-Pilon
        Lifelines: survival analysis in Python.
        J Open Source Softw. 2019; 4: 1317
        • Delgado A.
        • Guddati A.K.
        Clinical endpoints in oncology: a primer.
        Am J Cancer Res. 2021; 11: 1121-1131
        • Oishi K.
        • Itamoto T.
        • Amano H.
        • et al.
        Clinicopathologic features of poorly differentiated hepatocellular carcinoma.
        J Surg Oncol. 2007; 95: 311-316
        • Kamiyama T.
        • Nakanishi K.
        • Yokoo H.
        • et al.
        Analysis of the risk factors for early death due to disease recurrence or progression within 1 year after hepatectomy in patients with hepatocellular carcinoma.
        World J Surg Oncol. 2012; 10: 107
        • Kaibori M.
        • Ishizaki M.
        • Matsui K.
        • et al.
        Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma.
        J Surg Oncol. 2010; 102: 462-468
        • Xu L.
        • Hui A.Y.
        • Albanis E.
        • et al.
        Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis.
        Gut. 2005; 54: 142-151
        • Dou C.
        • Liu Z.
        • Tu K.
        • et al.
        P300 Acetyltransferase mediates stiffness-induced activation of hepatic stellate cells into tumor-promoting myofibroblasts.
        Gastroenterology. 2018; 154: 2209-2221
        • Kang N.
        • Shah V.H.
        • Urrutia R.
        Membrane-to-nucleus signals and epigenetic mechanisms for myofibroblastic activation and desmoplastic stroma: potential therapeutic targets for liver metastasis?.
        Mol Cancer Res. 2015; 13: 604-612
        • Asayama Y.
        • Yoshimitsu K.
        • Nishihara Y.
        • et al.
        Arterial blood supply of hepatocellular carcinoma and histologic grading: radiologic-pathologic correlation.
        AJR Am J Roentgenol. 2008; 190: 28-34
        • Hernandez-Gea V.
        • Toffanin S.
        • Friedman S.L.
        • et al.
        Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.
        Gastroenterology. 2013; 144: 512-527
        • Morisaka H.
        • Motosugi U.
        • Glaser K.J.
        • et al.
        Comparison of diagnostic accuracies of two- and three-dimensional MR elastography of the liver.
        J Magn Reson Imaging. 2017; 45: 1163-1170